Barclays initiates coverage of Abbott Laboratories with overweight rating and $120 target price
ABT•Barclays initiated coverage of Abbott Laboratories with an overweight rating and a $120 target price.
Related News
Triple Flag targets 2026 metal sales of 100,000-110,000 gold equivalent ounces
TFPM•
Boston Scientific names Joseph Fitzgerald as COO, effective Jan. 1, 2027
BSX•
Star Gold posts Longstreet PEA with $87 million pre-tax NPV and 48% IRR
SRGZ•
Health Canada approves Lipocine-partnered TLANDO for testosterone replacement therapy
LPCN•
National Health Investors updates financial calendar with third-quarter earnings release, conference call timing
NHI•